Conference Track

Current Issues in Antiretroviral Therapy

Source: CCO Independent Conference Coverage of the 2007 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Expert Analysis

Current Issues in Antiretroviral Therapy

Faculty:
Pedro Cahn, MD, PhD Roy M. Gulick, MD, MPH Joep MA Lange, MD, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:

Specify factors that may influence the choice of first-line antiretroviral regimens
Recall the results of recent studies utilizing investigational antiretroviral agents in treatment-naive and treatment-experienced HIV-infected patients
Describe considerations that may influence the initiation of first-line antiretroviral regimens in resource-limited settings
Discuss the impact of cessation of breast-feeding on infants born to HIV-infected mothers
Summarize recent data on the predictive value of viral load in determining CD4+ cell count decline and disease progression

Topics covered include:

Comparing Efavirenz vs Lopinavir/Ritonavir
TMC278-C204: Rilpivirine vs EFV
CCR5 and Integrase Inhibitors as First-Line Therapy
CCR5 and Integrase Inhibitors in Treatment-Experienced Patients
Elvitegravir/RTV vs CPI/RTV
Early Mortality in Resource-Limited Settings
Early Breast-feeding Cessation
HIV-1 RNA Set Point
Entecavir Anti-HIV Activity
Anti-HIV Activity of Acyclovir

CME CREDIT INFORMATION

Release Date: 04/30/07

Expiration Date: 04/29/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.3 contact hours (0.13 CEUs)

Registered Nurses: 1.3 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.